Emmaus Life Sciences (OTCMKTS:EMMA) Announces Quarterly Earnings Results

Emmaus Life Sciences (OTCMKTS:EMMA) announced its quarterly earnings results on Friday. The company reported $0.02 EPS for the quarter, Zacks reports.

Emmaus Life Sciences Price Performance

Shares of EMMA stock remained flat at $0.01 on Friday. The company had a trading volume of 90,008 shares, compared to its average volume of 69,714. The firm has a market cap of $807,185.00, a P/E ratio of -0.09 and a beta of 9.37. Emmaus Life Sciences has a one year low of $0.01 and a one year high of $0.02. The company has a 50-day simple moving average of $0.01 and a 200 day simple moving average of $0.01.

Emmaus Life Sciences Company Profile

Emmaus Life Sciences, Inc is a publicly traded specialty pharmaceutical company focused on the development and commercialization of therapies for sickle cell disease and other serious hematological disorders. Its lead product, Endari® (L-glutamine oral powder), received U.S. Food and Drug Administration approval in 2017 for reducing the acute complications of sickle cell disease in patients aged five years and older. Through targeted research and development, Emmaus is also advancing additional pipeline candidates aimed at addressing oxidative stress and protein aggregation pathways that underlie various blood disorders.

Emmaus markets Endari in the United States and has entered into licensing agreements to distribute the therapy in regions including sub-Saharan Africa, the Middle East, North Africa and Latin America.